EUVIMEDEUVIMED entdecken
Vergleichsstudie

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Izanne Roos iD, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott, Suzanne Hodgkinson, Raed Alroughani, Sara Eichau Madueño iD, Cavit Boz, Anneke van der Walt iD, Helmut Butzkueven, Katherine Buzzard und 34 weitere

Multiple Sclerosis Journal · 2024

DOI: 10.1177/13524585241267211 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Izanne Roos und 45 weiteren Autor:innen. Beteiligte Einrichtung: CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melb…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Cladribine, Alemtuzumab, Fingolimod Hydrochloride. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Health and Medical Research Council, Multiple Sclerosis Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking.

Objectives

To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS.

Methods

Patients with relapsing-remitting MS treated with cladribine, fingolimod, natalizumab, ocrelizumab or alemtuzumab were identified in the global MSBase cohort and two additional UK centres. Patients were followed for ⩾6/12 and had ⩾3 in-person disability assessments. Patients were matched using propensity score. Four pairwise analyses compared annualised relapse rates (ARRs) and disability outcomes.

Results

The eligible cohorts consisted of 853 (fingolimod), 464 (natalizumab), 1131 (ocrelizumab), 123 (alemtuzumab) or 493 (cladribine) patients. Cladribine was associated with a lower ARR than fingolimod (0.07 vs. 0.12, p = 0.006) and a higher ARR than natalizumab (0.10 vs. 0.06, p = 0.03), ocrelizumab (0.09 vs. 0.05, p = 0.008) and alemtuzumab (0.17 vs. 0.04, p < 0.001). Compared to cladribine, the risk of disability worsening did not differ in patients treated with fingolimod (hazard ratio (HR) 1.08, 95% confidence interval (CI) 0.47–2.47) or alemtuzumab (HR 0.73, 95% CI 0.26–2.07), but was lower for patients treated with natalizumab (HR 0.35, 95% CI 0.13–0.94) and ocrelizumab (HR 0.45, 95% CI 0.26–0.78). There was no evidence for a difference in disability improvement.

Conclusion

Cladribine is an effective therapy that can be viewed as a step up in effectiveness from fingolimod, but is less effective than the most potent intravenous MS therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingCladribineAlemtuzumabFingolimod HydrochlorideNatalizumabAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsHumansFemaleMaleAdultMiddle AgedImmunologic FactorsTreatment Outcome

Stichwörter der Autor:innen

Cladribinecomparative effectivenessmultiple sclerosisobservational studies

Substanzen

CladribineAlemtuzumabFingolimod HydrochlorideNatalizumabocrelizumabAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsImmunologic Factors

Autor:innen und Institutionen

  • CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Dokuz Eylul University, Konak, Izmir, Turkey.
  • Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia/John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia.
  • Immune Tolerance Laboratory Ingham Institute and Department of Medicine, UNSW, Sydney, NSW, Australia.
  • Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait.
  • Hospital Universitario Virgen Macarena, Sevilla, Spain.

ORCID-Profile: Izanne Roos, Sara Eichau Madueño, Anneke van der Walt, Nevin John, Michael Barnett, Jiwon Oh, Pierre Duquette, Emma Tallantyre, J William L Brown, Tomas Kalincik

Förderung

  • National Health and Medical Research Council
  • Multiple Sclerosis Australia

Zitieren

APA

Roos, I., Sharmin, S., Malpas, C., Ozakbas, S., Lechner-Scott, J., Hodgkinson, S., Alroughani, R., Eichau Madueño, S., Boz, C., van der Walt, A., Butzkueven, H., Buzzard, K., Skibina, O., Foschi, M., Grand'Maison, F., John, N., Grammond, P., Terzi, M., Prévost, J., …, & Kalincik, T. (2024). Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241267211

Vancouver

Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, et al. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241267211

BibTeX
@article{Roos2024,
  author = {Roos, Izanne and Sharmin, Sifat and Malpas, Charles and Ozakbas, Serkan and Lechner-Scott, Jeannette and Hodgkinson, Suzanne and Alroughani, Raed and Eichau Madueño, Sara and Boz, Cavit and van der Walt, Anneke and Butzkueven, Helmut and Buzzard, Katherine and Skibina, Olga and Foschi, Matteo and Grand'Maison, Francois and John, Nevin and Grammond, Pierre and Terzi, Murat and Prévost, Julie and Barnett, Michael and Laureys, Guy and Van Hijfte, Liesbeth and Luis Sanchez-Menoyo, Jose and Blanco, Yolanda and Oh, Jiwon and McCombe, Pamela and Ramo Tello, Cristina and Soysal, Aysun and Prat, Alexandre and Duquette, Pierre and Yamout, Bassem I and Khoury, Samia and van Pesch, Vincent and Macdonell, Richard and José Sá, Maria and Slee, Mark and Kuhle, Jens and Maimone, Davide and Spitaleri, Daniele LA and Willekens, Barbara and Asmi, Abdallah Al and Tallantyre, Emma and Robertson, Neil P and Coles, Alasdair and L Brown, J William and Kalincik, Tomas},
  title = {Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis},
  journal = {Multiple Sclerosis Journal},
  year = {2024},
  doi = {10.1177/13524585241267211}
}
Kostenlos starten →